CHINA RESOURCES PHARMACEUTICAL GR financial statements, including revenue, expenses, and profit
The total revenue of 3320 for the last semiannual is 140.02 B HKD, and it's 0.48% higher compared to the previous semiannual. The net income of H2 24 is 809.33 M HKD.